GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AC Immune SA (STU:IMR) » Definitions » Loans Receivable

AC Immune (STU:IMR) Loans Receivable : €0.00 Mil (As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is AC Immune Loans Receivable?

AC Immune's Loans Receivable for the quarter that ended in Mar. 2024 was €0.00 Mil.


AC Immune Loans Receivable Historical Data

The historical data trend for AC Immune's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AC Immune Loans Receivable Chart

AC Immune Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Loans Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

AC Immune Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Loans Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

AC Immune Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.


AC Immune Loans Receivable Related Terms

Thank you for viewing the detailed overview of AC Immune's Loans Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


AC Immune (STU:IMR) Business Description

Traded in Other Exchanges
Address
EPFL Innovation Park, Building B, Lausanne, CHE, 1015
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding.

AC Immune (STU:IMR) Headlines

No Headlines